Ketamine

Update Review Report

Agenda item 6.2

Expert Committee on Drug Dependence
Thirty-sixth Meeting
Geneva, 16-20 June 2014
Acknowledgements

This report has been drafted under the responsibility of the WHO Secretariat, Essential Medicines and Health Products, Policy Access and Rational Use Unit. The WHO Secretariat would like to thank the following people for their contribution in producing this critical review report: Dr Wim Best, the Netherlands (literature review and drafting), Dr Caroline Bodenschatz, Switzerland (editing) and Mr David Beran, Switzerland (questionnaire report drafting).
## Contents

Summary ............................................................................................................................................ 7

1. **Substance Identification** ................................................................................................................. 8
   A. International Non-proprietary Name (INN) .................................................................................. 8
   B. Chemical Abstract Service (CAS) Registry Number ................................................................. 8
   C. Other chemical names .................................................................................................................. 8
   D. Trade Names ............................................................................................................................... 8
   E. Street Names .............................................................................................................................. 8
   F. Physical properties ....................................................................................................................... 8
   G. WHO Review History ................................................................................................................. 9

2. **Chemistry** ..................................................................................................................................... 9
   A. Chemical Name .......................................................................................................................... 9
   B. Chemical Structure ................................................................................................................... 9
   C. Stereoisomers ............................................................................................................................ 9
   D. Synthesis ................................................................................................................................... 9
   E. Chemical description ................................................................................................................ 10
   F. Chemical properties ................................................................................................................ 10
   G. Chemical identification ......................................................................................................... 10

3. **Convertibility Into Controlled Substances** .................................................................................. 10

4. **General Pharmacology** .................................................................................................................. 10
   4.1. Pharmacodynamics ............................................................................................................... 10
   4.2. Routes of administration and dosage .................................................................................... 13
   4.3. Pharmacokinetics ................................................................................................................. 13

5. **Toxicology** ................................................................................................................................... 14

6. **Adverse reactions in humans** ........................................................................................................ 18

7. **Dependence potential** .................................................................................................................... 21

8. **Abuse potential** ......................................................................................................................... 29

9. **Therapeutic applications and extent of therapeutic use** ................................................................ 30

10. **Listing on the WHO Model List of Essential Medicines** .......................................................... 31

11. **Marketing authorizations (as a medicine)** .................................................................................. 31

12. **Industrial use** ............................................................................................................................. 31

13. **Non-medical use, abuse and dependence** .................................................................................. 31

14. **Nature and magnitude of public health problems related to misuse, abuse and dependence** ...... 32

15. **Licit production, consumption and international trade** ............................................................ 33

16. **Illicit manufacture and traffic and related information** ............................................................. 33

17. **Current international controls and their impact** ....................................................................... 34

18. **Current and past national controls** .......................................................................................... 34

19. **Other medical and scientific matters relevant for a recommendation on the scheduling of the substance** .................................................................................................................. 34

References ........................................................................................................................................... 35

Annex 1: Report on WHO questionnaire for review of psychoactive substances for the 36th ECDD: evaluation of ketamine .............................................................................................................. 43
Summary

Ketamine is chemically (±)-2-(2-chlorophenyl)-2-(methylamino) cyclohexanone (CAS No. 6740-88-1 for base, 1867-66-9 for hydrochloride (previous: 81771-21-3; 96448-41-8; 42551-62-2)). It is an arylcycloalkylamine structurally related to cyclidines, like eticyclidine, phencyclidine, rolicyclidine and tenocyclidine. This NMDA-receptor-antagonist is used as an anaesthetic in both human and veterinary medicine for short diagnostic and surgical procedures that do not require skeletal muscle relaxation.

Ketamine is marketed under many trade names. Preparations containing the S-enantiomer only are increasingly being marketed. It can produce a depression of the central nervous system, resulting in hallucinations, disturbances in thinking, perceptions and also in motor function. However, adverse events in patients are quite different from those found in recreational users.

Ketamine has been misused as a hallucinogen for almost 30 years. The effects are similar to those of phencyclidine, but with a much shorter duration. Dependence has been demonstrated in various animal models. There are some human data supporting this. Ketamine misuse is reported from a number of countries in Asia, Europe and North America. Misuse by medical personnel has also been reported.

It has already been placed under national control in almost 60 countries.

During its 35th meeting, the WHO Expert Committee on Drug Dependence discussed the critical review report on ketamine and came to the following recommendation: “Although we acknowledge the concerns raised by some countries and UN organizations, ketamine abuse currently does not appear to pose a significant global public-health risk. On the other hand if ketamine were placed under international control, this would adversely impact its availability and accessibility. This in turn would limit access to essential and emergency surgery, which would constitute a public-health crisis in countries where no affordable alternative anaesthetic is available. On this basis, we, the Expert Committee, decided that bringing ketamine under international control is not appropriate”.

The substance is difficult to synthesize, so illegal production is rare, but happens in some parts of the world, mainly China and India. There is significant legitimate use in hospitals and veterinary clinics. Diversion has been reported from some countries. It is not expected that diversion will take place on a large scale. International control may jeopardize the availability for medical and veterinary use. However, it is important for the international community to work in harmony to strike a balance between legitimate use of ketamine for medical and veterinary purposes and prevention of trafficking in and abuse of ketamine.
1. Substance Identification

A. International Non-proprietary Name (INN)
Ketamine; ketamine hydrochloride.

B. Chemical Abstract Service (CAS) Registry Number
6740-88-1 (free base)
1867-66-9 (current: hydrochloride salt)
81771-21-3; 96448-41-8; 42551-62-2 (previous: hydrochloride salt)

C. Other chemical names
2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride;
2-(o-chlorophenyl)- 2-(methylamino)cyclohexanone hydrochloride;
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone hydrochloride;
2-(methylamino)-2-(o-chlorophenyl)cyclohexanone hydrochloride;
cyclohexanone, 2-(2-chlorophenyl)- 2-(methylamino) hydrochloride;
cyclohexanone, 2-(o-chlorophenyl)- 2-(methylamino) hydrochloride.

D. Trade Names
Some of the trade names used include:
Anaket®, Anasket®, Anesketin®, Brevinase® Brevinaze®, Calypsol®,
Calypsovet®, Chlorketam®, Ereska®, Imalgene®, Inducmina®, Kalipsol®,
Katalar®, Keta®, Keta-Hameln®, Ketaject®, Ketalar®, Ketalin®, Ketalor®,
Ketamav®, Ketamax®, Ketamil®, Ketamin®-ratiopharm, Ketaminol Vet®,
Ketanarkon®, Ketanest®, Ketanest-S®, Ketaset®, Ketasol®, Ketava®,
Ketaved®, Ketavet®, Ketmine HCl®, Ketolar®, Ktmin®, Narkamon®,
Narketan®, Pan-Ketamine®, Ralatek®, S-Ketamin®, Tekam®, Velonarcon®
Vetaket®, Vetalar®, Vetus Ketha-Thesia®.

See additional brand names reported by countries in Annex 1, report of the
WHO Questionnaire for Review of Psychoactive Substances for the 36th
ECDD.

E. Street Names
A number of street names for ketamine can be found in the literature, like:
“Ketamine”, “K-Hole”, “Kit Kat”, “Liquid E”, “Liquid G”, “Mauve and
Green”, “1980 acid”, “Purple”, “Special K”, “Special LA coke”, “Super acid”,
“Super C”, “Super K”, “Tac et Tie”, “Vitamin K” (EMCDDA, 2002; Pagliaro
and Pagliaro, 2004).

One should be aware of the fact that street names are not always exclusive for
just one substance. Flatliners is also used for 4-MTA and Liquid E for GHB.

F. Physical properties
White to almost white, crystalline powder.
G. **WHO Review History**
During its 35th meeting, the WHO Expert Committee on Drug Dependence discussed the critical review report on ketamine and concluded that this information was not sufficient to warrant scheduling. However, the Committee was informed that the United Nations Commission for Narcotic Drugs at its XXth session, held in March 2013, had adopted a draft resolution on the listing of ketamine as a controlled substance. The Committee requested the Secretariat to produce an updated version of the critical review and present it to the next meeting of the Expert Committee on Drug Dependence.

2. **Chemistry**

   A. **Chemical Name:**
      IUPAC Name: 2-(2-Chlorophenyl)-2-(methylamino)-cyclohexan-1-one
      CA Index Name:

   B. **Chemical Structure**
      Free base:

      ![Chemical Structure](image)

      Molecular formula: \( C_{13}H_{16}ClNO \) (free base)  
                    \( C_{13}H_{17}Cl_2NO \) (hydrochloride salt)
      Molecular weight: 237.73 g/mol (free base)  
                        274.18 g/mol (hydrochloride salt)
      Melting point: 92-93°C (free base)  
                     262-263°C (hydrochloride salt)

   C. **Stereoisomers**
      Ketamine contains a chiral centre at the C-2 carbon of the cyclohexanone ring, so that two enantiomers exist: \( S^{(+)} \)-ketamine and \( R^{(-)} \)-ketamine. The \( S \)-enantiomer being the pharmacologically more active stereoisomer. Increasingly, the \( S^{(+)} \) enantiomer is being used in the commercially available preparations.

   D. **Synthesis**
      Ketamine is manufactured by the pharmaceutical industry. The preparation is described by Stevens, Belgian patent 634208 (1963), which corresponds to the U.S. patent 3254124 (1966 to Parke-Davis). The synthesis of the optical
isomers is described by Hudyma et al., German patent 2062620 (1971 to Bristol-Myers) (Budavari et al., 1989).

As the substance is difficult to synthesize, Ketamine for recreational use is obtained mostly by diversion of commercial sources. (Please also refer annex 1)

**E. Chemical description**

Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) is an arylcycloalkylamine structurally related to phencyclidine (PCP).

**F. Chemical properties**

Ketamine hydrochloride is a water-soluble, white crystalline powder and has a pKa of 7.5 (Budavari et al., 1989). Its free base, ketamine, has lipid solubility 10 times that of thiopentone. The commercially available pharmaceutical form is an aqueous solution for injection of the racemic mixture of the hydrochloride salt.

**G. Chemical identification**

Ketamine is metabolized to at least two compounds. The parent compound and both major metabolites are further transformed by hydroxylation and conjugation prior to elimination. About 90% of a dose is excreted in urine in 72 hours, with about 2% of the dose unchanged. There are different methods described in the literature to analyze KT in the urine. One of them is an analytical method using solid-phase extraction and positive ion chemical ionisation-gas chromatography-mass spectrometry (Kim E.M. et al., 2008).

3. **Convertibility into controlled substances**

Ketamine is not converted into controlled substances.

4. **General pharmacology**

The pharmacology of ketamine will be described in two parts. The first one will deal with the effects of the substance on various neurotransmitter systems related to both its clinical use and its use as a recreational agent. The second part will deal with the effects on various organ systems often wanted in clinical or veterinary practice or occurring during non-medical use and sometimes leading to adverse reactions.

4.1. **Pharmacodynamics**

Ketamine is a dissociative anaesthetic (Domino et al., 1966). Originally, the dissociation component refers to a functional and electrophysiological dissociation of thalamocortical and limbic systems (Reich and Silvay, 1989; Haas and Harper, 1992). More recently, the nature of the subanaesthetic ketamine experience has led to the use of the term ‘dissociative’ in a more psychological sense referring to a feeling of dissociation of the mind from the body (Jansen, 1990; 2000a).

Ketamine binds to the so-called PCP-binding site of the N-methyl-D-aspartate (NMDA)-receptor complex, located within the ion channel, thereby blocking the
transmembranous ion flux. This makes ketamine a non-competitive NMDA-receptor antagonist. NMDA-receptors are calcium-gated channel receptors. The endogenous agonists of this receptor are the excitatory amino acids glutamic acid, aspartic acid, and glycine. Activation of the receptor results in opening of the ion channel and the depolarisation of the neurone. The NMDA-receptor is involved in sensory input at the spinal, thalamic, limbic and cortical levels. Ketamine would be expected to block (or interfere with) sensory input to higher centres of the CNS, with the emotional response to these stimuli, and with the process of learning and memory (Bergman, 1999).

Awakening from ketamine anaesthesia takes place at plasma concentrations of 0.64-1.12 µg/ml (Reich and Silvay, 1989). Psychotropic effects have been described in the presence of plasma concentrations ranging from 50 to 300 ng/ml and with regional brain concentrations higher than 500 ng/ml (Bowdle et al., 1998; Oranje et al., 2000; Hartvig et al., 1995).

Several studies indicate that opioid receptors are also involved in the pharmacological effects of ketamine (Freo, 2002), and that the analgesic effect of ketamine may largely be attributed to the activation of these central and spinal receptors (Crisp et al., 1991).

The plasma levels at which analgesia is achieved are 0.15 µg/ml following intramuscular administration and 0.04 µg/ml after oral administration. This difference may be explained by a higher norketamine concentration due to first-pass metabolism. This main metabolite apparently contributes to the antinociceptive effect of ketamine (Shimoyama et al., 1999).

Furthermore, new developments show strong interactions between the opioid and the NMDA system in the brain of animals. In contrast to earlier findings, new results point to NMDA receptors and not sigma-receptors as having a role in the morphine withdrawal response (Brent et al., 1993). Gonzalez et al. (1997) have shown that competitive and non-competitive NMDA receptor antagonists prevent morphine tolerance and decrease the development of physical dependence on this opiate in mice. The study of Ji et al. (2004) indicates that ketamine has the ability to suppress morphine withdrawal syndrome in experimental settings without motor interference. The nucleus accumbens (NAc) is mentioned as the site of action.

Some effects of ketamine may be due to its actions on catecholamine systems, notably an enhancement of dopamine activity (White and Ryan, 1996; Vollenweider et al., 2000; Smith et al., 1998). A series of experiments by Hancock and Stamford (1999) on the effects of ketamine on uptake and efflux of dopamine in the rat NAc led the authors to conclude that ketamine increases NAc dopamine efflux not by the blocking of dopamine uptake, autoreceptors or NMDA receptors, but by mobilisation of the dopamine storage pool to releasable sites. In the rat, it has been shown that repeated ketamine administration diminished the initial five-fold increase in dopamine release in the prefrontal cortex, whereas the increase in extracellular 5-hydroxyindole acetic acid (a serotonin metabolite) levels is enhanced. This suggests that the balance between dopamine and serotonin neurotransmission in the prefrontal cortex is altered after repeated exposure to ketamine (Lindfors et al., 1997). The dopaminergic effects may be of relevance for the euphorigenic, dependence-producing and psychotomimetic properties of ketamine.
Other neuropharmacological actions are an agonistic effect on α- and β-adrenergic receptors, an antagonistic effect at muscarinic receptors of the CNS, and an agonistic effect at the σ-receptor (Bergman, 1999).

The principal metabolite, norketamine, is pharmacologically active. Its binding affinity to the NMDA-receptor and anaesthetic properties are approximately one third of the parent compound contributing significantly to the analgesic effect of ketamine (Shimoyama et al., 1999).

The commercially available ketamine is a racemic mixture of two enantiomers. The S-enantiomer is shown to be the more potent one with an approximately 3-4 fold anaesthetic potency compared to the R-enantiomer. This correlates with the higher binding affinity for the PCP-site of the NMDA-receptor. The psychotomimetic properties of ketamine are mainly caused by the S-enantiomer, although subanaesthetic doses of R-ketamine may induce a state of relaxation (Vollenweider et al., 1997; Engelhardt, 1997).

**Effects on the cardiovascular system**

Ketamine differs from most anaesthetic agents in that it appears to stimulate the cardiovascular system, producing changes in heart rate, cardiac output, and blood pressure (Haas and Harper, 1992). Possibly, re-uptake inhibition of circulating catecholamines may contribute to this phenomenon. On the other hand, cardiodepressant effects have been noted in critically ill patients. This may be due to chronic catecholamine depletion preventing any sympatomimetic effects of ketamine and unmasking a negative inotropic effect, which is usually overshadowed by sympathetic stimulation (White and Ryan, 1996; Reich and Silvay, 1989). The cardiovascular effects of ketamine usually do not pose a problem, but its use is contraindicated in patients with significant ischaemic heart disease and should be avoided in patients with a history of high blood pressure or cerebrovascular accidents (Haas and Harper, 1992). In recreational ketamine users, presenting to an emergency department, tachycardia was the most common finding upon physical examination (Weiner et al., 2000).

**Effects on the respiratory system**

Ketamine is a mild respiratory depressant. It causes a shift of the CO₂ dose–response curve to the right, in a dose-related manner, but does not change the slope of the curve. Respiratory drive to CO₂ may be depressed as much as 15 to 22%. This effect is similar to that of opioids, but dissimilar from most sedative hypnotics and anaesthetics, suggesting that opioid receptors may play a role in the respiratory depressant effect. In clinical studies, the effects were observed only at high doses. Some case reports describe respiratory depression after rapid intravenous injection, but also after routine paediatric use of ketamine administered intramuscularly (Reich and Silvay, 1989; White and Ryan, 1996). At recreational doses, respiratory depression is not likely to occur, but cannot wholly be excluded.

Ketamine has a bronchodilatory effect and pharyngeal and laryngeal reflexes are maintained (Reich and Silvay, 1989).
Other pharmacological effects
Ketamine increases muscle tone (Reich and Silvay, 1989).
Blood glucose and plasma cortisol and prolactin are increased after ketamine administration (Reich and Silvay, 1989; Krystal et al., 1994).
Ketamine may decrease intraocular pressure (Reich and Silvay, 1989).

4.2. Routes of administration and dosage

Clinically, the medicine is usually administered by intramuscular or intravenous injection. For analgesia, the intrathecal route is used as well. Also, the oral and the rectal routes have been described (Reich and Silvay, 1989).

A dose equivalent to 2 mg of ketamine per kg body-weight given intravenously over 60 seconds usually produces surgical anaesthesia within 30 seconds lasting for 5-10 minutes (dose may range from 1 to 4.5 mg/kg); an intramuscular dose equivalent to 10 mg per kg body-weight (range 6.5-13 mg/kg) usually produces surgical anaesthesia within 3 to 4 minutes lasting for 12 to 25 minutes (Reynolds et al., 1989).

Analgesia is obtained by administration of 0.2-0.75 mg/kg intravenously (Reich and Silvay, 1989).

Subanaesthetic doses inducing psychotropic effects range from 0.1 to 1.0 mg/kg i.v. In clinical studies, this dose may be divided into a bolus of 0.1-0.2 mg/kg and a maintenance infusion of 0.0025-0.02 mg/kg/min. (Krystal et al., 1994; Engelhardt, 1997; Malhotra et al., 1996; Vollenweider et al., 1997; Oranje et al., 2000).

Intramuscular administration of ketamine in a dose range from 25 to 200 mg has been reported to produce psychotropic effects in humans (Hansen et al., 1988). Malinovsky et al. (1996) found that bioavailability of nasally administered ketamine in children was approximately 50%, whereas bioavailability of intramuscularly administered ketamine is approximately 93% (Grant et al., 1981).

4.3. Pharmacokinetics

The reported volume of distribution varies from 1.5 to 3.2 l/kg. The clearance is in the range of 12-28 ml/(kg.min). The volume of distribution and clearance for S-ketamine are 9 and 14% greater than those for R-ketamine, respectively (Engelhardt, 1997).

Absorption
Ketamine is rapidly absorbed when administered through the intramuscular (Tmax 5-15 min), nasal (Tmax 20 min) or oral route (as a solution) (Tmax 30 min). Bioavailability is low when ketamine is given orally (17%) or rectally (25%). Extensive first-pass metabolism in liver and intestine is largely responsible for this effect. Bioavailability after nasal administration is approximately 50% (Malinovsky et al., 1996). This may partly be caused by significant swallowing of the fairly large intranasal deposit.

Distribution
Ketamine has a high lipid solubility and low plasma protein binding (12%), which facilitates rapid transfer across the blood–brain barrier. Initially, it is distributed to highly perfused tissues, including the brain, to achieve levels 4-5 times those in plasma
Ketamine

(distribution half-life after i.v. 24 sec.). CNS effects subside following redistribution to less well-perfused tissues (re-distribution half-life, 2.7 min.).

**Biotransformation**

Biotransformation primarily takes place in the liver. The most important pathway is N-demethylation to norketamine. When administered orally or rectally, initial plasma norketamine concentrations are higher than those of ketamine, but the plasma area under the curve (AUC) for norketamine is similar for all routes of administration. Norketamine has one-third the anaesthetic potency of ketamine and has analgesic properties. Norketamine may be metabolised through multiple pathways, but the largest part is hydroxylated and subsequently conjugated.

**Elimination**

The predominant route of elimination is by liver metabolism. The high extraction rate (0.9) makes ketamine clearance susceptible to factors affecting blood flow. The conjugated hydroxy metabolites are mainly excreted renally. Terminal elimination half-lives range from 100-200 minutes.

**Pharmacokinetic interactions**

Ketamine, and its primary metabolite, norketamine, are metabolised by enzymes from the cytochrome P450 (CYP) family. In a recent study, it has been shown that ketamine induces the expression of multiple forms of P-450 in rat liver microsomes and increases CCl4-induced liver toxicity and cocaine-mediated acute toxicity (Chan *et al.*, 2005). As the combination of cocaine and ketamine is used and known in the party scene (as CK or Calvin Klein), these findings should lead to further investigations into the possible risks for users of this combination.

5. **Toxicology**

The clinical safety profile of ketamine is largely based on extensive clinical experience. The preclinical data may therefore be of less importance. However, in contrast to recreational use, long-term clinical use of ketamine is rare. Therefore, some preclinical data may be of greater importance for the recreational substance user than for clinical practice.

**Animal**

**Single-dose toxicity**

Single dose acute toxicity shows an LD₅₀ between 140 (intraperitoneally in the neonatal rat) and 616 mg/kg bw orally in the mouse (EMEA, 1997). In adult mice and rats, LD₅₀ values were 224±4 mg/kg and 229±5 mg/kg, respectively (route not indicated) (Budavari *et al.*, 1989).

In squirrel monkeys (Greenstein, 1975), doses above 25 mg/kg i.v. caused anaesthesia. At the highest concentration tested (350 mg/kg) 4 out of 5 monkeys died. In humans, the lowest recommended i.v. dose to induce anaesthesia is 1 mg/kg. Applying the same ratio of minimal anaesthetic dose to highest non-lethal dose to humans implies that doses above 11.3 mg/kg i.v. may be lethal in humans. For a person of 60 kg this is equivalent to i.v. doses above 680 mg. This estimate is based on an experiment with a low number of animals and interindividual and interspecies differences may exist. Yet,
considering data from case reports of fatal ketamine intoxications in humans, this estimate seems to be a realistic one. Several studies investigated the local tolerance of ketamine when administered intrathecally (e.g. Errando et al., 1999; Malinovsky et al., 1993). Ketamine, when injected without preservative did not cause neurotoxicity in the spinal cord of swine or rabbits.

*Repeated-dose toxicity*

In rats daily intravenous doses of 2.5, 5 or 10 mg/kg bw for 6 weeks provoked a slight but not significant decrease of food intake and moderate weight gain depression (EMEA, 1997).

In a toxicological repeated toxicity study in dogs, 3 groups of 4 animals were given daily intramuscular doses of 4, 20 or 40 mg/kg bw during 6 weeks. At all dose levels there was some degree of weight loss and anorexia. Some blood parameters were also elevated and dose-related. Histological changes in the liver were minor (EMEA, 1997).

*Reproduction function*

Rats were injected during the pre-mating period (10 mg/kg bw i.v. on Days 9, 10 and 11 prior to mating). No effect on litter size was observed (EMEA, 1997).

*Embryo-fetal and perinatal toxicity*

Summarizing the available literature, at doses ten times those used in humans for anaesthesia, histopathological changes in rat foetuses have been observed. These effects are dependent on the period of exposure. Based on these preclinical data, in the absence of sufficient toxicokinetic data in animals, and considering that rodents have a higher metabolic rate and doses administered were in the subanaesthetic range in these animals, it cannot be excluded that ketamine in (sub)anaesthetic doses may adversely affect pregnancy outcome in humans (Bandazhevskii and Shimanovich, 1991; El-Karim and Benny, 1976; Kochhar et al., 1986; Hammer and Herkenham, 1983).

Other studies in rats and rabbits point in the same direction but have limited value, since the duration and level of exposure in these studies do not meet current standards of toxicity testing (EMEA, 1997).

A study in female dogs, injected with 25 mg/kg bw intramuscularly six times during one trimester of pregnancy did not show apparent adverse effects on the bitch or the pups (EMEA, 1997).

No data on human pregnancies exposed to ketamine exist (Friedman, 1988). There is some clinical evidence during use of ketamine during parturition, where it has been shown that ketamine may depress fetal functions when 2 mg/kg (i.v.) is administered to the mother.

Two studies will be discussed in more detail below as they deserve more attention because of possible serious consequences for users of party-drugs, especially in combination with other such substances.

Abdel-Rahman and Ismael (2000) studied the teratogenic potency of ketamine hydrochloride in CF-1 mice with and without cocaine. It was shown that ketamine (50 mg/kg/day) potentiates the teratogenic effects of cocaine (20 mg/kg/day), but was not
teratogenic on its own. Considering the higher metabolic rate of mice, the authors stated that the doses applied were comparable to those used by dependent humans and should be toxic to first-time users. As also shown in the study by Chan et al. (2005) the combination of cocaine and ketamine is a deleterious one.

Olney and co-workers (2000) suggested that ketamine has the potential to delete large numbers of neurones from the developing brain by a mechanism involving interference in the action of neurotransmitters [glutamate and gamma-aminobutyric acid (GABA) at N-methyl-D-aspartate (NMDA)] and GABA A receptors during the synaptogenesis period, also known as the brain growth-spurt period. Transient interference (lasting less than or equal to 4 hr) in the activity of these transmitters during the synaptogenesis period (the last trimester of pregnancy and the first several years after birth in humans) causes millions of developing neurones to commit suicide (die by apoptosis).

**Mutagenic and carcinogenic potential**

Taking all the information together, the published data from genotoxicity testing of racemic ketamine are insufficient and do not allow for a reasonable assessment of the genotoxic potential of ketamine. Whereas negative findings were obtained in poorly conducted (compared to current standards) bacterial tests, a positive result was reported from a sister chromatid exchange (SCE) test *in vitro*. However, the effects observed in the SCE study were only weak (i.e. less than a doubling of control values) and thus the relevance of this finding is questionable. Moreover, unpublished data (submitted to the German Federal Institute for Drugs and Medical Devices as part of an application for a marketing authorization) from genotoxicity testing with the S- (+) enantiomer of ketamine in a standard battery of validated *in vitro* and *in vivo* tests did not reveal any evidence of a genotoxic potential. Provided that the genotoxicity findings with the S- (+) enantiomer of ketamine can be extrapolated to the racemate, it can be concluded that ketamine is highly unlikely to possess any relevant genotoxic properties (Adhvaryu et al., 1986; Waskell, 1978).

**Carcinogenic potential**

No data on the carcinogenic potential of ketamine are available.

**Immunotoxicity**

As previously mentioned the combination of cocaine with ketamine is currently popular among young substance misusers. Rofael et al. (2003) did a series of investigations in rats in order to elucidate the possible mechanism of action. From the experiments, it can be concluded that cocaine has immunotoxic properties possible by neuro-endocrinal mechanisms. These effects may at least in part be counteracted by ketamine. The immunotoxic effects of cocaine may especially be detrimental in vulnerable groups, like people with HIV or hepatitis-infections.

**Neurotoxicity**

One issue that has been investigated in animals, but has received little attention in the clinical literature and that may be of importance for especially the recreational user of ketamine, is the neurotoxicity as observed in rats (Olney et al., 1989; 1991).

When administered subcutaneously, ketamine (40 mg/kg) caused vacuolisation in posterior cingulate and retrosplenial cerebrocortical neurones in the rat. Lower doses (≤20 mg/kg) did not cause such pathological changes. These highly localised neurotoxic
effects have been shown for other NMDA-antagonists as well (Olney et al., 1989; 1991; Auer, 1994; O’Callaghan, 1994).

After intrathecal administration to rabbits, postmortem investigation of the spinal cord and nerve roots revealed histopathological lesions suggestive of toxic damage in 11 rabbits, from a group of 12 receiving S(+)-ketamine. In 5 control animals, no histological changes were observed. Nevertheless there was no significant difference in neurological status between the two groups after 7 days of intrathecal treatment (Vranken et al., 2006).

Also in rhesus monkeys, neuronal cell death has been reported, but this was very much dependent on the stage of development of the animal and the duration of administration. Electron microscopy indicated that ketamine-induced neuronal cell death is most likely to be both apoptotic and necrotic in nature (Slikker et al., 2007).

The mechanism for this neurotoxic response is proposed to be based on a NMDA-antagonist-mediated hypofunction of the NMDA-receptor, resulting in a combination of enhancement of excitatory neuronal pathways and inhibition of inhibitory neuronal pathways that lead to and from specific groups of neurones in the cingulate and retrosplenial cerebral cortices. Consistent with this hypothesis, it has been shown that several classes of drugs effectively inhibit the neurotoxic effects of the NMDA antagonists, including a) muscarinic receptor antagonists, b) (GABA)A-receptor agonists (such as benzodiazepines), c) σ-receptor antagonists, d) non-NMDA (kainic acid) receptor antagonists, e) α2-adrenergic receptor agonists, f) some typical antipsychotic agents (for instance haloperidol) and g) atypical antipsychotic agents (clozapine, olanzapine) (Bergman, 1999). It may be anticipated that substances with opposite pharmacological actions to those classes of drugs mentioned here may enhance the neurotoxicity of ketamine. In this context, from the recreational drug repertoire should be mentioned: Amanita muscaria mushrooms (muscarinic agonist), alcohol (NMDA- and (partial) GABA A-antagonist), yohimbine (α2-adrenergic receptor antagonist), and other dissociative drugs like PCP and tiletamine.

Two recent publications give additional insights into the possible mechanisms of the neurotoxicity of ketamine. Wang et al. (2005) show that upregulation of the NMDA receptor subunit NR1 following ketamine administration is, at least, partially responsible for the observed apoptosis. And Liao et al. (2004) describe the induction of the expression of HSP70 by ketamine and also that ketamine injures the neurons of rat hippocampus, and the higher the dose given, the more serious the injury is. Furthermore, ketamine induces a higher level of HSP70 expression in adult rats than in infant rats. A more pronounced neurotoxic effect in adult rats is also mentioned as a result of the investigations of Beals et al. (2004) - an effect ketamine shares with nitrous oxide, another NMDA-antagonist also used in the party scene.

There may be several reasons why these findings in rats have not led to the abandonment of the clinical use of ketamine. First, ketamine is generally accepted as a safe anaesthetic without long-term adverse effects (Shorn and Whitwam, 1980; Reich and Silvay, 1989). Therefore, the preclinical data are considered of limited clinical relevance. Secondly, benzodiazepines are usually co-administered with ketamine to reduce the occurrence of emergence phenomena (for a description, see below Human, Clinical experience). Benzodiazepines have been shown in rats to protect against the ketamine-induced neurotoxicity.
Contrarily, there may be reasons why the findings on the neurotoxicity of ketamine in the rat may be of concern to recreational users of ketamine. First, substance users will not take ketamine in combination with protective agents like benzodiazepines. Moreover, compounds increasing the neurotoxic potency of ketamine might be co-administered. Secondly, recreational use implies repeated exposure, whereas clinical use is mostly incidental. Long-term adverse effects in long-term users of ketamine have been reported, however are scarce. These included persisting impairment of attention and recall and a subtle visual anomaly (Jansen, 1990). A review on internet reports from heavy users of ‘dissociatives’ (i.e. dextromethorphan, ketamine and PCP) is summarised. Effects mentioned after frequent use were “jolts” or “shocks” when moving the eyes, sharply impaired visual tracking, impaired recognition of metaphor, impaired language skills and memory problems. These adverse effects (that fade with time) are related by the author to malfunction of or damage to the cingulate and retrosplenial cortices. To date, there is insufficient evidence to ascertain such a relationship in humans.

6. Adverse reactions in humans

Human

Clinical experience
Ketamine is considered to be an anaesthetic with a good safety profile (Reich and Silvay, 1989). Its major drawback, limiting its clinical use, is the occurrence of emergence reactions. Emergence phenomena in patients awakening from a ketamine narcosis have been described following early clinical experience, and include hallucinations, vivid dreams, floating sensations and delirium. These symptoms were found to be reduced by concurrent use of benzodiazepines, putting the patient in a low stimulus environment and by providing information on the possible emergence reactions preoperatively. These emergence phenomena appear to occur more frequently in adults (30-50%) than in children (5-15%) (White and Ryan, 1996; Bergman, 1999).

No adverse outcomes were noted in nine healthy children treated in the emergency department who inadvertently received 5 to 100 times the intended dose of ketamine. Toxicity manifested as prolonged sedation in all nine and brief respiratory depression in four of the children. The margin of safety in ketamine overdose may be wide (Green et al., 1999).

Respiratory depression
In two cases, a severe respiratory depression has been described after co-administration of ketamine. In one case, it appeared after premedication with secobarbital in a seven-year-old patient given a subanaesthetic dose of ketamine (approximately 3.3 mg/kg i.m.) (Kopman, 1972). In the other case, ethanol was involved with a fatal ending (Moore et al., 1997).

Sympathicomimetic effects
Serious side effects like hypertension and lung edema have been reported (Murphy, 1993). Such adverse effects appear to be rare and may be related to the combination of ketamine with other substances of abuse.
This may be due to the sympathicomimetic properties of ketamine. Inhibition of central catecholamine re-uptake and increased levels of circulating catecholamines are believed to cause the cardiovascular stimulant effects.

On the other hand, cardiodepressant effects have been noted in critically ill patients. This may be due to chronic catecholamine depletion and so preventing any sympathicomimetic effects of ketamine and unmasking a negative inotropic effect, which is usually overshadowed by sympathetic stimulation (White and Ryan, 1996; Reich and Silvay, 1989).

Noppers et al (2011) showed that after prolonged and/or repeated infusion of S(+)ketamine liver injury may occur.

In their study six patients were scheduled to receive 2 continuous intravenous 100-hour S(+)ketamine infusions (infusion rate 10-20mg/h) separated by 16 days. Three of them developed hepatotoxicity after the start of the second infusion.

**Non-medical experience**

**Fatal intoxications**

In the EMCDDA report, a short overview is given of 13 reported deaths in which recreational use of ketamine was involved.

The following conclusions can be drawn from the data as presented in the report:

- Only in 3 out of 13 cases of fatal intoxications was ketamine solely identified. It was administered by injection. Two reports describe mixed drug fatalities. In the other cases ketamine had either a minor role or there was a lack of data for a proper evaluation.

- In contrast to what is known from non-medical use where usually lower dosages are used, the ketamine blood concentrations in the described cases were in the anaesthetic range or above. Where clues about the quantity administered were available, such indicators suggested amounts of approximately 1 g administered i.v. or i.m. in the absence of other substances. Based on a body weight of 60 kg, such a dose is 4-17 times the recommended i.v. dose for anaesthesia or 1.3-2.5 times the recommended i.m. dose for anaesthesia. The i.v. data are in line with preclinical findings. In squirrel monkeys death occurred when ketamine was administered (i.v.) at a dosage more than ten times the dose producing anaesthesia (Greenstein, 1975). The relatively small margin of safety for the acute toxicity applying the i.m. route cannot be explained without any further investigation. From a clinical point of view it is at least not expected.

In the subgroup of multiple substance users, the ketamine concentrations found are lower than those found in the few cases involving ketamine only. This indicates that drug interactions may play a significant role in contributing to these deaths. In this respect, substances with CNS/respiratory depressant effects, like ethanol, opioids, barbiturates, and benzodiazepines, or substances with cardiostimulant effects, like cocaine and amphetamines, are indicated as drugs that may increase ketamine toxicity.

Benzodiazepines can have favourable effects in clinical practice as co-administration prevents the occurrence of emergence phenomena (as described above). But when used
simultaneously in a recreational setting without proper monitoring of vital functions, they may enhance the respiratory and CNS-depressant effects of ketamine.

In an article by Gill and Stajic (2000), all ketamine-positive deaths (87) over a two-year period (1997 to 1999) examined at the New York City Office of Chief Medical Examiner were reviewed. There were 15 non-hospital deaths with 12 due to acute multidrug intoxications. In no instance was a fatal intoxication caused exclusively by ketamine. Opiates, amphetamines and cocaine were the most frequent co-intoxicants. Ethanol was found in only one death.

In 2004 two other cases were published in which the use of ketamine was fatal (Lalonde and Wallage 2004). One case strongly points to ketamine as the sole factor responsible for the fatal ending. In the other case the presence of asthma as co-morbidity factor cannot be excluded.

In a letter to the editor, Schifano et al. (2008) present an overview of all of the ketamine-associated deaths in the UK over the period 1993-2006. Twenty three cases are presented but in only four cases ketamine has been identified postmortem as the sole substance present. Blood levels have not been measured and a direct contribution of ketamine to the deaths could not be established.

The WHO Uppsala Monitoring Centre (UMC) reported, out of 1277 reports from adverse effects from world wide PMS-data, over a 2-year period, 25 cases of death, (2.0 %) and 1 case of sudden death (0.08%) (unpublished, communication to WHO, 2005).

**Non-fatal intoxications**
From the available data on non-fatal intoxications after the use of ketamine by recreational users, the following conclusions can be drawn (Siegel, 1978; Dalgarno and Shewan, 1996; Weiner et al., 2000):

The main effects are neurobehavioural:

- anxiety (especially in first-time users),
- agitation (Arditti, 2000),
- changes of perception (e.g. loss of notion of danger, visual disturbances),
- disorientation and impairment of motor function, such as ataxia (Arditti, 2000) and dystonic reaction (Felser and Orban, 1982).

In such a condition, the misusers will have severely impaired self-control, which poses a risk for injury for him or her self or others (e.g. when participating in traffic).

Common side-effects reported by users were:

- slurred speech,
- dizziness,
- blurred vision,
- palpitations,
- chest pain,
- vomiting, and
- insomnia.
The predominant symptom found on physical examination in users that went to an emergency department was tachycardia (Weiner et al., 2000). Rhabdomyolysis was noted in several cases (Weiner et al., 2000). Other physical side-effects appear to be rare.

Some other effects less often reported were:

- neuropathy of Guillain-Barré type and some physical effects such as general stiffness, increase of body temperature (38 °C),
- hepatic crises,
- myalgia and
- mydriasis.

Since several years lower urinary tract symptoms have been described as a new adverse effect of ketamine misuse (Chu et al., 2008, Colebunders and Van Erps, 2008, Shahani et al., 2007). Meanwhile more and more cases have been described in the literature (see for an overview Li et al, 2013). Based on a survey by Winstock et al (2012) one can assume that there is underreporting of the problem. In their survey 1285 participants reported ketamine use within the last year (33.8%). Of the ketamine users 340 of recent ketamine users (26.6%) reported experiencing urinary symptoms.

The earlier cases presented show cystitis and bladder dysfunction, an increase in urinary frequency, urgency, dysuria, urge incontinence and occasionally painful haematuria. Secondary renal damage can occur in severe cases. Chen et al (2013) described the first case of renal infarction after nasal insufflation use of ketamine.

Another recently described phenomenon is ulcerative cystitis (Jalil and Gupta, 2012, Chen et al, 2011).

The urinary tract symptoms were significantly related to both the dose of ketamine used and the frequency of ketamine use. After cessation of the use most of the symptoms disappeared gradually over time.

Not only does ketamine impair the urinary tract but it also affects the liver and biliary tract in a negative way. Jaundice and biliary dilatation occur after recreational use of ketamine (Gutkin et al, 2012).

The negative effect on urinary tract and biliary tract often coincides.

7. Dependence potential

Behavioural studies in animals

Self-administration

Animal models of dependence are used to test the induction of substance-taking behaviour which might be similar to the recreational use of ketamine. To date there are no animal models that incorporate all the elements of dependence. The observation that animals readily self-administer drugs has led to the argument of face-validity, and psychologically this is based on the reinforcing properties of a compound. This animal
model has also a high predictive validity, although there are some limitations (Willner, 1997; Koob et al., 1998).

Early assessments of the reinforcing properties of ketamine reported that rhesus monkeys shown to self-administer intravenously metamfetamine or cocaine also self-administered ketamine (3.2-1600 microg/kg/inj) under limited access conditions at an intense schedule of reinforcement. An inverted U-shaped dose–response curve was observed. A variation of the fixed ratio so that the animals have to put more effort to obtain their reward, produced an orderly increase in the response rate with a factor of 3 (Moreton et al., 1977). Increasing the fixed ratio on PCP administration, however, eliminated the responding on PCP (Marquis and Moreton, 1987) suggesting a higher intrinsic power of reinforcement for ketamine, which might be more related to the depressant action of the substance than to the psychotomimetic action. In baboons, however, self-administration was obtained at a FR160 schedule (Lukas et al., 1984) both for ketamine and PCP, suggesting that the observed difference between ketamine and PCP might be specific to rhesus monkeys. No obvious behavioural changes occurred during exposure to doses of 10-32 microg/kg. A ten-fold higher dose of PCP was associated with sedation and ataxia. Food intake was unaffected by the lower doses.

From data in various species, it appears that substance intake tends to increase slightly with increases in unit dose in each species. However, the increase is of a lesser degree that generally occurs with the self-administration of CNS depressants such as pentobarbital and morphine (Marquis and Moreton, 1987).

**Drug discrimination**

Animals are able to give an indication as to how a drug makes them “feel” with the drug-discrimination paradigm, in a behavioural method offering animals a choice and reinforcing them by pelleted food if their choice is correct depending on the treatment (drug or saline or another drug). This drug-discrimination approach is a powerful method to differentiate between subjective feelings (called the stimulus) of drugs, e.g opioids from psychomotor stimulants. It is well-established that the drug–response data in this respect can be handled as pharmacological data showing selectivity and sensitivity.

It is well-recognized that drug-discrimination paradigms can be used also for non-dependence-producing drugs. However, when carefully designed, such studies might be certainly of value in the assessment of common subjective states produced by drugs (Schuster and Johanson, 1988).

Drug-discrimination data from a series of stereoisomers of compounds generalising to PCP or ketamine indicate that compounds exhibiting reinforcing properties comparable to PCP share similar stimulus properties of this pharmacological class (Shannon, 1981; Young et al., 1981).

**Tolerance and withdrawal**

A number of studies have demonstrated tolerance to the effects of ketamine (White and Ryan, 1996). This type of acute tolerance is related to changes at the site of action rather than any increase in rate of metabolism, as it was shown to be induced after one injection, without changing the plasma concentration.
Continuous IV infusion of PCP and ketamine at maximum tolerated dosages in rats was used to demonstrate whether dependence could be induced by these compounds. The animals were trained to lever press for their daily food rations under an FR30 schedule of reinforcement. Withdrawal of PCP as well as ketamine markedly reduced response rates, providing evidence of dependence. Readministering the compounds, the rates increased rapidly to control rates, providing evidence of reversal of withdrawal. Cross-tolerance and withdrawal from ketamine to PCP was described. Observable withdrawal signs have been reported for rhesus monkeys with unlimited access to ketamine self-administration.

Rats, chronically exposed to ketamine, exhibited subcortical withdrawal seizures without gross behavioural manifestations for up to 5 days after self-administration was discontinued (White and Ryan, 1996)

**Behavioural studies in man**

*Acute effects*

Studies investigating the pathophysiology of schizophrenia, using ketamine as a model substance, and studies investigating the psychotropie effects of ketamine in their own right, have provided a good characterisation of the psychotomimetic action of ketamine (e.g. Krystal et al., 1994; Vollenweider et al., 1997; 2000; Malhotra et al., 1996; Adler et al., 1999; Oranje et al., 2000; Hartvig et al., 1995; Bowdle et al., 1998). It appears that ketamine in subanaesthetic doses induces a state of mind that both neurophysiologically and behaviourally resembles that of a schizophrenic psychosis, but that may be experienced by the experimental or recreational substance user as an altered, ‘psychedelic’, state of mind that allows him to travel beyond the boundaries of ordinary existence.

*Effects on cognitive functioning (neuropsychological assessment)*

Ketamine acutely affects cognitive performance, including attention, working memory and semantic memory.

Hartvig et al. (1995) showed in a double-blind randomised crossover study with five healthy volunteers that short-term memory could be impaired dose-dependently by administration of 0.1 and 0.2 mg/kg (i.v.), as assessed by a word recall test. Ketamine binding in the brain correlated well with the regional distribution of NMDA-receptors.

Ketamine hydrochloride (0.1 or 0.5 mg/kg i.v. during 40 minutes) did not produce a significant effect on the mini-mental state examination (a brief bedside evaluation of cognition) in healthy subjects (n=18), however tests of vigilance, verbal fluency, and the Wisconsin Card sorting test showed a dose-dependent impairment (Krystal et al., 1994). Delayed word recall was reduced, but immediate and post-distraction recall were spared.

Malhotra et al. (1996) assessed the effects of ketamine (total dose 0.77 mg/kg i.v. during 1 hour) on attention, free recall of categorically related words and recognition memory of categorically related words. All three cognitive functions showed significant decrements. Memory impairments were not accounted for by the changes in the subjects' attention and did not correlate to psychosis ratings. In further studies, Adler et al. (1998) found that ketamine induced thought disorder significantly, correlated with
decrements in working memory, but did not correlate with ketamine-induced impairments in semantic memory.

Narendran et al. (2005) demonstrated that chronic ketamine users exhibit a regionally selective up-regulation of D1 receptor availability in the dorsolateral prefrontal cortex, an effect also seen after chronic dopamine depletion in animal studies. These data suggest that the repeated use of ketamine for recreational purposes affects prefrontal dopaminergic transmission, a system critically involved in working memory and executive function.

**Effects on emotional status, behavioural patterns and personality (psychological instruments, rating scales)**

Ketamine profoundly affects perception of body, time, surroundings and reality. A study in ten psychiatrically healthy volunteers was performed by Bowdle et al. (1998). The subjects were administered an escalating dose of ketamine by i.v. infusion with plasma target concentration of 50, 100, 150 and 200 ng/ml. Each step was maintained for twenty minutes and the subjects were asked to rate various aspects of their consciousness on a visual rating scale (VAS). A good correlation between the plasma ketamine concentrations and the VAS ratings was obtained.

The following VAS scores were increased by ketamine, compared with a saline control:

- **Body:** Body or body parts seemed to change their position or shape.
- **Surroundings:** Surroundings seemed to change size, depth or shape.
- **Time:** The passing of time was altered.
- **Reality:** There were feelings of unreality.
- **Thoughts:** There was difficulty controlling their thoughts.
- **Colours:** The intensity of colours changed.
- **Sound:** The intensity of sound changed.
- **Voices:** Unreal voices or sounds were heard.
- **Meaning:** Subjects had the idea that events, objects, or other people had particular meaning that was specific for them.
- **High:** They felt high.
- **Drowsy:** They felt drowsy.
- **Anxious:** They felt anxious.

The intensity of the effects was greatest for high, reality, time, surroundings, thought and sound. They were lowest for anxiety and meaning.

This study clearly shows there is a dose–effect relationship between the ketamine dose and the intensity of the ‘psychedelic’ effects. All but one participant spontaneously reported feelings of intoxication and perceptual distortion during the ketamine infusion; one of these persons also reported such symptoms during the placebo infusion. Three participants became moderately dysphoric during the ketamine infusion, but not during the placebo infusion.

Krystal et al. (1994) also included VAS of mood states in their study in 18 healthy volunteers after administration of 0.1 or 0.5 mg/kg ketamine hydrochloride i.v. for 40 minutes. They observed a biphasic effect on anxiety, the low dose decreasing anxiety
and the high dose increasing anxiety. VAS rating for high was increased dose-dependently.

Hartvig et al. (1995) studied the psychotomimetic effect of low doses (0.1 and 0.2 mg/kg i.v.) ketamine in a double-blind randomised crossover study in five healthy volunteers. All subjects having peak plasma ketamine concentrations of 70 ng/ml or above or estimated peak regional brain ketamine concentrations of 500 ng/ml or above experienced psychotomimetic effects. These consisted of pronounced feelings of unreality, altered body image perception, sensations of impaired recognition of the limbs, detachment from the body, and modulation in hearing, characterised by preoccupation with unimportant sounds. The intensity of the effects showed a dose–response relation with the degree of regional brain binding of ketamine.

Vollenweider and coworkers (1997) investigated the differential effects of S- and R-ketamine and found that S-ketamine is responsible for the psychotomimetic effects, whereas R-ketamine induced a state of relaxation. Results of a mood rating scale for S-ketamine showed increased scores for ‘deactivation’, ‘introversion’, negative and dysphoric feelings and anxiety. All subjects reported distortion of body-image, loosening of ego-boundaries, and alterations of the sense of time and space, variously associated with emotional changes ranging from euphoria (30%), indifference (30%) or heightened anxiety (40%).

In an open uncontrolled study (Hansen et al., 1988), seven individuals working in health care explored the psychotropic effects of ketamine for its use as a possible adjunct in psychotherapy by intravenous, intramuscular and oral self-administration of various subanaesthetic doses. They recorded that their inner experiences were extremely intense and possessed a subjective quality, which made it difficult to put them in writing. To a certain extent, they varied from one subject to another and even for the same subject from one session to another. Nevertheless, all of the subjects had experienced most of the following phenomena:

- A sensation of light throughout the body;
- novel experiences concerning "body consistency" (e.g., being described as made up of dry wood, foam rubber, or plastic);
- grotesquely distorted shape or unreal size of body parts (e.g., extremely large or small);
- a sensation of floating or hovering in a weightless condition in space;
- radiantly colourful visions (e.g., images of moving from one room to another filled with moving, glowing geometrical patterns and figures);
- complete absence of time sense (i.e., an experience of virtual timelessness or eternity);
- periodic, sudden insight into the riddles of existence or of the self;
- occasionally, an experience of compelling emotional consanguinity, at times extending to sensations of melting together with someone or something in the environment; and
- an experience of leaving the body (i.e., out-of-body experience).

In nearly every instance, subjects retained the sense of a sober, witnessing "I" that could both observe and consider as well as be amazed, overjoyed or perhaps anxious, and that could, to a certain extent, later remember the unusual phenomena.
In the EMCDDA report (2002) a more extensive overview of the effects, including the near-dead effect, described by the participants is given.

**Effects on psychopathological status - psychiatric comorbidity (psychological and psychiatric assessment)**

Studies in healthy volunteers given ketamine and schizophrenic patients have shown that ketamine produces a clinical syndrome with aspects that resemble key symptoms of schizophrenia.

Krystal *et al.* (1994) assessed both four key positive and three key negative symptoms of schizophrenia in healthy subjects after administration of 0.1 or 0.5 mg/kg ketamine hydrochloride i.v. during 40 minutes. The positive symptoms were conceptual disorganisation, hallucinatory behaviour, suspiciousness, and unusual thought content. The negative symptoms were blunted affect, emotional withdrawal, and motor retardation. Ketamine produced a dose-dependent increase in scores for both positive and negative symptoms.

Similarly, scores for key symptoms of schizophrenia (conceptual disorganisation and disorganised speech, unusual thought content, emotional withdrawal, psychomotor retardation and blunted affect) were increased by ketamine (Malhotra *et al.*, 1996). Adler and co-workers (Adler *et al.*, 1998; 1999) studied the effects of ketamine on thought disorder and compared these effects with thought disorder in patients with schizophrenia. They found similar scores for 19 of 20 items on the Scale for the Assessment of Thought, Language and Communication. Only the score for the item ‘perseveration’ was lower in schizophrenic patients. However, after Bonferroni correction this difference was no longer statistically significant.

A total dose of 0.56 mg/kg ketamine over 125 minutes was infused in healthy volunteers (n=19) to obtain a pseudo steady state plasma ketamine concentration of 134 ng/ml. Reduced processing negativity and P300 amplitude, psychophysiological anomalies, commonly observed in schizophrenic patients, were recorded. However, no drug effect on mismatch negativity, another parameter commonly reduced in schizophrenic subjects, was found (Oranje *et al.*, 2000).

Vollenweider and coworkers (2000) observed a negative correlation between raclopride’s binding potency in the ventral striatum and S-ketamine-induced euphoria-and mania-like symptoms, suggesting a role for elevated striatal dopamine levels in these positive symptoms.

**Chronic effects**

**Effects on cognition, mood and mental functioning**

Short-term exposure to ketamine appears not induce any long-term adverse effects on cognition, mood or personality. Long-term heavy use of ketamine may be associated with persisting deficits in attention and recall. However, such a condition has been documented only once in the literature.

**Clinical studies in volunteers**

In a follow-up interview in a study by Krystal *et al.* (1994) of healthy volunteers given ketamine hydrochloride (0.1 or 0.5 mg/kg), no subject had lingering or recurrent
physiological or psychological effects, such as nightmares, flashbacks, or perceptual alterations following a test day.

The subjects in the study of Hansen et al. (1988) did not report any long-term side effects of any nature for up to three years following the ketamine sessions.

Corsen et al. (1971) studied 30 volunteers from a prison population that were given either ketamine or thiopentone or served as control. Psychological assessment was performed before, at 1 week, 4 weeks and 6 months after substance administration. They could not establish a difference between the three groups.

**Studies in patients**

Psychological changes were assessed in 221 patients following ketamine anaesthesia and compared with patients receiving other anaesthetics. Psychometric tests were applied repeatedly for more than 1 year (Albin et al., 1970). There were no significant differences between groups in terms of mental performance, hallucinations and behavioural factors.

Seven case reports of prolonged (several weeks to up to 1 year) psychic phenomena after single (or in one case dual) exposure were reviewed by Steen and Michenfelder (1979). In one patient, serious effects persisted for 5 days, in three others there were only minor disturbances for 3 weeks, in two patients severe congenital brain abnormalities were present, and in one patient complaining of hallucinations and “passing out spells” and feelings of unreality and hesitation, it could not be excluded that these symptoms were linked to a single dose exposure to ketamine 1 year earlier, but this seems unlikely.

**Studies in recreational users**

Siegel (1978) stated that subjects who reported long-term use of ketamine sometimes complained of “flashbacks”, attentional dysfunction and decreased sociability. Positive effects on mood were mentioned as well, which reinforced and maintained substance use. However, standard psychometric tests did not reveal personality changes. The subjects described were mostly polydrug users, those snorting ketamine also using cocaine. Contrarily to the PCP group, that was described in the same paper, a tendency to transient psychosis was not noted.

Amongst 20 recreational substance users studied by Dalgaro and Shewan (1996), lasting psychological effects were not reported. Eleven of them used ketamine less than 10 times, 8 used it between 10 and 20 times and only one user reported use of approximately 100 occasions. The last subject, who was an experienced poly substance user, reported "a total loss of reality" during a month-long ketamine binge, after which he stopped completely without major difficulties. Subsequently, he reported having very lucid dreams similar in nature to the ketamine-induced state. These dreams lessened in intensity and ceased completely within 7 to 10 days of the final ketamine episode.

Jansen (1990) described a case in which a subject had persisting impaired recall and attention and a subtle visual anomaly after cessation of long-term high-dose ketamine use.
Morgan et al. (2004) looked at the effect of ketamine in recreational users direct after use and 3 days later. On Day 0, ketamine users were impaired on both source memory and item recognition and scored more highly on schizophrenic and dissociative symptom scales compared to poly substance controls. On Day 3 ketamine users only displayed source memory impairments and these positively correlated with the level of schizophrenic-like symptoms on Day 0. No differences on Day 3 in schizophrenic-like or dissociative symptoms were observed. These findings suggest that repeated use of ketamine produces chronic impairments to episodic memory.

In order to find out if these deficits might be reversible upon reduction or cessation of ketamine use or are long-lasting, the group of Morgan et al. (2004) performed an additional study in which they looked at ketamine users, already tested 3 years earlier. Meanwhile, this group of ketamine users had reduced their frequency of use of ketamine by an average of 88.3%. Performance of ketamine users on tasks tapping semantic memory had improved and this improvement was correlated with their reduction in ketamine use. On tasks tapping episodic memory and attentional functioning, ketamine users still showed deficits compared to poly substance controls. Higher levels of schizotypal symptoms and perceptual distortions were exhibited by the ketamine group, although dissociative symptoms were similar to controls. These findings indicate that semantic memory impairments associated with recreational use of ketamine are reversible upon marked reduction of use; however, impairments to episodic memory and possibly attentional functioning appear long-lasting. In addition, schizotypal symptoms and perceptual distortions may persist after cessation of ketamine use.

Only a very limited number of cases (less than 15) of ketamine dependence over the past 20 years have been described (Blachut et al., 2009; Bobo and Miller, 2002; Critchlow, 2006; Florkowski and Ferfecki, 1987; Lim, 2003; Pal et al., 2002). Unfortunately the use of terms is not well-defined and therefore one can not be sure that the cases presented here are really dealing with ketamine dependence. Almost half of the cases deal with healthcare staff (Moore and Bostwick, 1999; Rusek et al., 1988) as they have easily access to this kind of products. Furthermore multdrug use or polysubstance is one of the features these people have in common.

**Tolerance**

Tolerance to ketamine develops quickly and can be high. In one case report, the subject relates the history of his ketamine use. During the first 2 years his consumption developed from an occasional 50 mg oral dose to 500 mg four to five times a day. Switching to intramuscular injection, he was injecting 300-750 mg five to six times a day within a month. The tolerance dissipated on stopping the habit, but redeveloped at the same rate (within a month) after restarting intramuscular injections (Kamaya and Krishna, 1987).

**Abstinence symptoms**

There is no evidence that ketamine causes an abstinence syndrome in humans. The subject described in the case report by Kamaya and Krishna (1987) found stopping the habit extremely difficult, but never experienced a withdrawal syndrome.

Amongst 20 recreational ketamine users described by Dalgarno and Shewan (1996), 11 reported to never having experienced mental after-effects and 8 said never to have experienced physical after-effects following a ketamine episode. Of those that did have
mental after-effects, three reported a general feeling of well-being, two had a desire for physical contact, two felt mildly depressed and "flat", and two said they were "dopey" (feeling like being under the influence of cannabis). Of those that reported physical after-effects, three reported a general feeling of contentment and happiness, four said they felt mildly "hung over" or drained, three reported vomiting, one said he felt physically and positively changed and one felt nauseous.

Jansen (2000b) states that an elevated mood after a ketamine binge is common, whereas a cocaine-like swing into depression is rare. He suggests that high levels of norketamine can take days to subside, thereby providing a "deflating cushion". However, for such a theory no evidence is provided. In rats, norketamine-induced anaesthesia and locomotor activity are of shorter duration than when these effects are induced by ketamine. Both ketamine and norketamine are rapidly cleared from blood and brain (Leung and Baillie, 1986).

Substance -seeking behaviour and dependence
A distinction may be drawn between experimental (Ahmed and Petchkowsky, 1980) and dependent ketamine use (Kamaya and Krishna, 1987; Hurt and Ritchie, 1994). In dependent users, use of the substance continues despite increasing apparent effects on their work or on their health. Amongst the 20 users described by Dalgarno and Shewan (1996), seven had used ketamine once or twice and only three had used 15 times or more. One user in this group reported that he had believed the experience was "never going to end" and another experienced extreme dissociation. These two never repeated their first-time use. It appears that the dissociative experience discourages some experimental users. Another reason for limited use mentioned in this study was the scarcity of the substance. On the other side of the spectrum, one user in this study group said he believed he had been dependent on the use of ketamine during his heaviest period of ketamine use.

According to Jansen (2000b), tolerance to the effects of ketamine develops, and with higher doses the ability to remember the experience is sharply reduced. Where many stop at this point, others carry on with compulsive binges. These result in cocaine-like stimulation, opioid-like calming, cannabis-like imagery (which also disappears), alcohol-like intoxication, and relief from anxiety, depression, and mental craving (Jansen, 2000b). Jansen states that repeated users of ketamine may rapidly become dependent. This dependence-promoting nature of ketamine may be prominent for those that carry on with compulsive binges. No sound data on the prevalence of long-term use are available.

Three well-known ketamine histories are those of John Lilly (1978), Marcia Moore (1978) and D.M.Turner (1994). The first still seemed to use ketamine at the age of 83, even though at some point in his life elected hospitalisation for ketamine withdrawal. The second, according to her husband, Howard Altounian, became dependent and committed suicide. The third slipped below the waterline in his bathtub, with a half-empty bottle of ketamine on its side.

8. Abuse potential
No systematic studies on personality traits or other psychological factors leading to ketamine use or affecting the probability of harm were found. Psychological factors that
increase the probability of harm include, mood and anxiety conditions leading to self-medication, and sensation seeking.

Jansen (2000b) describes several conditions that may drive the use of ketamine. Amongst these is a characteristic of the ketamine experience, which may be described as escape from reality. Few substances offer such a strong experience of entering a different reality, which is not only experienced as differently, but also as no less real than reality without the substance. This possibility for escape and discovery may appeal to some individuals, especially those that have discontent with their ordinary existence and are looking for sense and meaning in their life. The ketamine experience offers in this way a psychological reward, which contributes to the development of dependence.

In those involved in taking substances as much and as many as possible, the sensation-seeking factor will certainly be important (Laviola et al., 1999). Ketamine, advertised as The Ultimate Psychedelic Journey (Turner, 1994), will appeal to substance users looking for extremes.

9. Therapeutic applications and extent of therapeutic use

Ketamine hydrochloride is used as an analgesic and anaesthetic in human and veterinary medicine, where it has acquired a unique place. Registered indications for ketamine use are listed in Annex 1 report on WHO Questionnaire for Review of Psychoactive Substances for the 36th ECDD.

Important clinical applications are mainly brief procedures in paediatric and ambulatory anaesthesia, its use in the treatment of burning wound patients, obstetrics and for the induction and maintenance of anaesthesia in hypovolemic, pericardial tamponade, constrictive pericarditis, and cardiogenic shock patients (Reich and Silvay, 1989; Bergman, 1999; Haas and Harper, 1992).

Its use in veterinary anaesthesia, especially in small animals, as well as in exotic animals, is widespread. Several Member States indicate that ketamine is indispensable for its indications in veterinary medicine.

Outside the EU, the use of ketamine as an anaesthetic in human medicine may have a more prominent place in developing countries, where facilities are much poorer. The ease of use gives ketamine a major advantage under the more difficult circumstances encountered (Green et al., 1996).

The pharmaceutical form of the preparations used in medicine is an injectable solution of the racemic mixture of ketamine hydrochloride in water. The solution is packaged in small glass sealed vials.

In several countries, the racemic mixture has already been replaced by a formulation containing the S-(+)-enantiomer only.

As the molecular action of substances used in medicine is better understood due to new techniques and insights, new indications or applications for well-established products, like ketamine, may emerge.
At this moment, the following new indications for ketamine have been investigated and published:

- Analgesia, for instance in patients resistant to opioids (Akin et al., 2005). Also other routes of application are being investigated, like the intranasal route (Bell and Kalso, 2004) – an unexpected by-product from the non-medical use. Another development in this field is the use of lower, so-called subanaesthetic doses (Smith et al., 2001).

- Psychotherapy, either as an adjunct to the psychotherapeutic process (Hansen, 1988) or as a chemical adjuvant in the treatment of dependence to alcohol (Krupitsky and Grinenko, 1997) or heroin (Krupitsky et al., 2002, Krupitsky et al., 2007). The treatment of alcoholism is based on the effects of ethanol on the NMDA-receptor complex with which also ketamine interacts (Krystal et al., 2003, Krystal et al., 2003).

10. Listing on the WHO Model List of Essential Medicines

Ketamine is listed as an anaesthetic both in EML 18th ed (2013) and in EMLc 4th ed (2013).

11. Marketing authorizations (as a medicine)

Ketamine is authorized as a medicine at least in 60 countries including the United States of America and the European Union. See also annex 1, report of the WHO Questionnaire for Review of Psychoactive Substances for the 36th ECDD.

12. Industrial use

Not applicable.

13. Non-medical use, abuse and dependence

The most popular route of administration, when ketamine is used recreationally or experimentally, is the intranasal route, i.e. snorting the powder, or a solution from a vaporiser. Some long-term users may use the intramuscular, subcutaneous or intravenous route as well. In the rave scene, oral administration by way of ketamine-containing tablets occurs as well.

Recreational users snorting the powder, describing the quantity as a ‘typical line’, suggest a quantity between 60 and 250 mg (Dalgarno and Shewan, 1996).

Ketamine was first marketed in the early 1970s (FDA, 1979), and promoted as a more acceptable alternative to its congener PCP (“Angel dust”) (Dotson et al., 1995). PCP was abandoned, except for veterinary use, because of its adverse effects such as hallucinations and delirium. Although ketamine is not devoid of similar side effects, these are less persistent.

Ketamine misuse was first spotted at the West Coast of the USA in 1971 (Siegel, 1978). In the early 1990s in the UK, several reports of a more widespread recreational use of ketamine appeared (Hall and Cassidy, 1992; McDonald and Key, 1992; Jansen, 1993;
Dalgarno and Shewan, 1996). An inquiry of the EMCDDA has shown that recreational use of ketamine is noted in other EU Member States as well (Arditti, 2000).

Although the contemporary dance drug scene is a global phenomenon with many countries, France, Canada, USA, Scotland, Australia, and cultures (Arditti et al., 2002; Barrett et al., 2005; Chengzheng et al., 2004; Clatts et al., 2005; Gross et al., 2002; Riley et al., 2001) reporting similar developments with ecstasy and other club drug use, the scene, in many respects, is a reflection and expression of local culture. During the last few years the term ‘club drugs’ has been used for defining an heterogeneous group of chemical substances in permanent evolution, that are consumed for recreational purposes. These substances have been extensively used, firstly by the Rave culture and later by the so called Club culture. These movements are characterized by the search of amplified sensations, by means of the combination of electronic music, marathon dancing and substance misuse. After years with a predominating consumption of amphetamine type stimulants in these groups, it seems that the use of another type of substances is increasing, fundamentally substances with hallucinogenic effects, such as ketamine (Abanades et al., 2004).

Besides these more mainstream groups, several smaller groups have been identified in which ketamine is misused. For instance a subset of gay men also taking more sexual risks (Lee et al., 2003), but also homeless and runaway youth (Lankenau and Clatts, 2004; Van Leeuwen et al., 2004). Other harms that require further investigation are the association between ketamine and unsafe sex and injecting behaviours, and use in situations where there is an increased risk of accidental death when the user's cognition is grossly impaired (Degenhardt et al., 2005).

Although a lot of research groups are investigating the use of recreational substances, no solid epidemiological data are present. Top et al. (2004) describe the Australian Illicit Drug Reporting System (IDRS) and its feasibility of monitoring trends in the markets for ‘party drugs’. The trial demonstrated that the system would allow the successful monitoring of markets for party drugs that are relatively widely used, such as ecstasy, but would be less sensitive in monitoring markets for party drugs that are used by small proportions of the total population, such as gamma-hydroxybutyrate (GHB) and ketamine.


14. Nature and magnitude of public health problems related to misuse, abuse and dependence

Copeland and Dillon (2005) give an overview of the health and psycho-social consequences of ketamine use. Information on ketamine is not routinely collected in population surveys and morbidity and mortality data collections. Levels of use in the general population, however, appear to be very low with higher levels in groups with access to the substance, such as medical and veterinarian professionals, and party drug users. There are a number of potential ketamine effects that may be seen as adverse or harmful, with growing evidence of the symptoms of ketamine dependence among recreational ketamine users. A withdrawal syndrome, including psychotic features, is beginning to be described. The use of ketamine with other neurotoxic drugs, such as
alcohol, should be avoided. Increased rates of high risk sexual and injecting behaviours in association with ketamine use, however, have been reported by gay men and marginalised youth in the US. The conclusion of the authors is that ketamine does not appear to currently pose a significant public health risk.

Although a number of countries did bring it under national control the recreational use did not decrease. Public health problems have not been published during the past ten years. But there is increasing evidence for the appearance of urinary tract problems after the use of ketamine during a prolonged period and or in high doses. Recently also biliary tract problems have been described (see section 6). But in contrast to the increasing number of publications on physical problems caused by ketamine there are no published reports on the dependence of ketamine in recreational users.

15. **Licit production, consumption and international trade**


16. **Illicit manufacture and traffic and related information**

In letters to the WHO the International Narcotics Control Board (INCB) gave a number of examples of misuse and trafficking.

In the past due to the difficult chemical synthesis of ketamine only diversion from legal sources has been observed. For instance in Mexico a veterinary pharmaceutical laboratory was dismantled that had manufactured large quantities of ketamine and sold them over the Internet to the United States. Or in France where an armed robbery took place in early April 2007 at the site of a company trading in pharmaceutical raw materials. The robbers disappeared with an amount of 1.3 kilogrammes of ketamine raw material. By using an intermediate company an unknown party attempted to divert 1000 kg of ketamine from India on its way to a company in Kenya.

The INCB report (2012) mentions that 99% of all ketamine seizures worldwide in 2009 took place in Asia. Countries that reported seized material are China (including Hong Kong and Macao both SAR of China), Taiwan, India, Indonesia, Australia, Canada and El Salvador.

Ketamine is illicitly manufactured in China, although India is also an important source of ketamine seized in the region. It is difficult to give an indication of the amount of the clandestine ketamine labs that are dismantled because often more than one illicit drug is manufactured. And not always is specified which lab makes what product.

Hydroxylamine hydrochloride, a precursor used in the manufacture of ketamine has been placed under national control in China in 2009.

In the period 2003-2012, a number of clandestine ketamine laboratories were seized in Indonesia and the Philippines.
With most of the illicit ketamine originating from the Asian region it is not a big surprise that it is one of the most abused drugs in that area. But ketamine also finds its way to the rest of the world due to smuggling and trafficking.


17. **Current international controls and their impact**

Ketamine is currently not under international control by the international drug control conventions. It may be argued that over the years a situation of de facto international control has emerged due to both CND resolutions and the INCB collecting data from Member States. There are several CND resolutions on ketamine and INCB reports have included data on ketamine for several years.

18. **Current and past national controls**

As of 1 December 2013, a total of 105 countries and territories have responded to the INCB. Of these, 63 countries and territories have already introduced an import authorization requirement for ketamine, and 57 countries and territories have introduced an export authorization requirement. 42 countries and territories do not require an import authorization and 48 do not require an export authorization.


19. **Other medical and scientific matters relevant for a recommendation on the scheduling of the substance**
References


Ketamine


Hall CH, Cassidy J. Young drug users adopt "bad trip" anaesthetic. Independent 1992;2 April:5.


Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44: 31-4
McDonald P, Key T. Ketamine: trick or treat? The Face 1992;45:45-46.
Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004;99:1450-61.
O’Callaghan JP. Biochemical analysis of glial fibrillary acidic protein as a quantitative approach to neurotoxicity assessment: advantages, disadvantages and application to the assessment of NMDA receptor antagonist-induced neurotoxicity. Psychopharmacol Bull 1994;30:549-54.
Olney JW, Farber NB, Wozniak DF, Jevtovic-Todorovic V, Ikonomidou C. Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain. Environ Health Perspect 2000;108:383-388.
Riley, Sarah C.; James, Charlotte; Gregory, Danielle; Dingle, Henry; Cadger, Mike. Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction. 2001 Jul;96(7):1035-1047.

Risner ME. Intravenous self-administration of phencyclidine and related compounds in the dog. J Pharmacol Exp Ther 1982;221:637-44.


Annex 1:
Report on WHO Questionnaire for Review of Psychoactive Substances for the 36th ECDD: Evaluation of Ketamine

Data were obtained from 72 WHO Member States (18 AFR, 13 AMR, 5 EMR, 29 EUR, 3 SEAR, 4 WPR).

A total of 67 Member States answered the questionnaire for Ketamine. Of these 64 respondents (AFR 14, AMR 13, EMR 3, EUR 27, SEAR 3, WPR 4) had information on this substance.

LEGITIMATE USE

Sixty-two respondents, representing all WHO regions (AFR 14: AMR 13; EMR 3; EUR 25; SEAR 3; WPR 4), stated that Ketamine was currently authorized as a medical product in their country. Based on the responses, ketamine had been in use since as early as 1962. The most common use is in anesthesia for many different procedures and surgeries. It is used for induction and maintenance. It is also used for sedation and in animals for immobilization. Ketamine was being used as liquid for injection with strengths of 10mg/ml; 50mg/ml; 100mg/ml; and 200mg/ml. Three respondents mentioned that Ketamine was for hospital use only.

Different brand names for Ketamine mentioned by respondents are shown in table below.

<table>
<thead>
<tr>
<th>Name</th>
<th>Number of mentions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketamine/Ketamina/Generic Ketamine</td>
<td>20</td>
</tr>
<tr>
<td>Ketalar</td>
<td>14</td>
</tr>
<tr>
<td>Calypsol</td>
<td>9</td>
</tr>
<tr>
<td>Anesket</td>
<td>5</td>
</tr>
<tr>
<td>Ketador</td>
<td>4</td>
</tr>
<tr>
<td>Ketaminol</td>
<td>4</td>
</tr>
<tr>
<td>Ketanset</td>
<td>3</td>
</tr>
<tr>
<td>Imalgene</td>
<td>3</td>
</tr>
<tr>
<td>Ketasol</td>
<td>2</td>
</tr>
<tr>
<td>Inducmina</td>
<td>2</td>
</tr>
<tr>
<td>Ketalin</td>
<td>2</td>
</tr>
<tr>
<td>Ketanir</td>
<td>2</td>
</tr>
<tr>
<td>Narketan, Tekam, Ketaject, Ketavit, Ketajex, Cost, Clortamina, Inresa, Vetaket, Ketanarckon, Ketaset, Kanox, Ketava, Avaket, Bioketan, Ketas Klorketam, Ketanil, Ket-A-100, S-Ketamin</td>
<td>1 each</td>
</tr>
</tbody>
</table>

Seventeen respondents mentioned that Ketamine was being used in medical and scientific research in their country. Ketamine was used in animal care by 43 respondents. Forty-four respondents stated that their countries imported Ketamine, 4 manufactured Ketamine in their own country and 2 both manufactured in their own country and imported Ketamine. The reported estimated quantities needed varied from a few kg to over 1000 kg. Many countries did not have such information or reported use as numbers of vials, ampoules etc.
HARMFUL USE

Twenty-eight respondents confirmed that there was recreational/harmful use of Ketamine while 12 stated there is no such use. Misuse was not reported from AFRO and EMRO regions. One respondent stated that 6.6% of general population used the substance based on a crime survey. Six respondents stated that the common route of administration was oral, six others oral/injection/ inhaling/sniffing, five inhaling/sniffing, three injection only, three oral/ injection, one injection/ inhaling/sniffing and one oral/ inhaling/sniffing. Ketamine was obtained for such use through diversion plus trafficking in 12 responses, trafficking only in six responses, diversion only in three responses, and diversion plus trafficking plus clandestine manufacturing in one response. Ketamine formulations available for recreational/harmful use were reported as liquid by eight respondents, powder by five, powder, tablet and liquid by five, tablet and liquid by three and powder and liquid by two. Its use was reported as only in clubs by 10, by the general population and in clubs by 2, and only in the general population by one. One overdose death was reported in 2012 by one respondent. Addiction programme enrolment were reported as 25 and 869 by two respondents. Emergency room visits reported by three respondents were 3, 5 and 20 for 2012 and 1,550 (equal to 0.5 visits per 100,000 population) in 2011. Nine respondents reported withdrawal, tolerance and other adverse effects or medical illnesses caused by Ketamine. These include catalepsis, hypertension, tachycardia, headache, nausea, vomiting, and respiratory depression, out of body, near death experiences. Long-term use is reported to cause memory loss and cognitive disabilities, heart damage, damage of the nervous system, digestive and urinary systems, causing serious abdominal pain, frequent urination, urinary urgency and dysuria, self-harm. Increased sex desire and hallucinations, delusions and other psychotic symptoms, can lead to aggression and thus affect public safety. It is reported to cause tolerance, craving and dependence. Information suggesting increasing use and decreasing use are provided by one country each.

CONTROL

Of those providing information on this substance, 55 reported that ketamine was controlled under legislation that was intended to regulate its availability; 29 under “controlled substance act”, 19 under “medicines law”, 1 under “analogue legislation”, 3 under “generic legislation” and 3 under “other” laws. Nine respondents stated that there were challenges with the implementation of this legislation, including resources and laboratory capacity. On illicit activities involving ketamine, four respondents reported processing into the consumer product, 15 reported trafficking, 14 reported diversion and 12 an internet market.

Details on seizures are presented below.

<table>
<thead>
<tr>
<th></th>
<th>2011 (number of respondents)</th>
<th>2012 (number of respondents)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of seizures*</td>
<td>2,150 (11)</td>
<td>2,070 (12)</td>
</tr>
<tr>
<td>Total quantity seized (kg)</td>
<td>5,549.03 (11)</td>
<td>4,198.78 (11)</td>
</tr>
<tr>
<td>Total quantity seized (L)</td>
<td>44.60 (4)</td>
<td>30.98 (4)</td>
</tr>
<tr>
<td>Total quantity seized (ampoules)</td>
<td>11 (3)</td>
<td>76 (3)</td>
</tr>
</tbody>
</table>

* Five more reported zero seizures for 2011 and 2012
IMPACT OF SCHEDULING

Fifty respondents reported that if Ketamine was placed under international control, they would have the laboratory capacity to identify the substance. Six respondents indicated that availability of ketamine for medical use will be affected if placed under international control.